Global rollout of the fluralaner product Bravecto and strengthening of the production system
First written in FY2017. 12 of 29 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「The livestock product lineup includes the drinking-water additive for controlling poultry red mites (a type of blood-sucking mite) in chickens, marketed under the brand name Exzolt®**, which has been approved in Asia, including Japan, as well as Europe, South America, Africa and the Middle East. The number of registered countries exceeded 70 as of March 2026. Products for controlling fleas and ticks in cattle, mainly in Brazil and Mexico, and products for controlling lice in sheep in Australia and New Zealand are also being sold.」
While maintaining its existing global expansion, the Company had registered Exzolt in more than 70 countries as of March 2026 and expanded into cattle and sheep products. - FY2026-H1ReframedAnnual report
「Fluralaner (active pharmaceutical ingredient for veterinary drugs) generated revenue at approximately the same level as the previous year.」
Fluralaner, which had been described as generating higher revenue in the interim period of the previous fiscal year, generated revenue at approximately the same level as the previous year in the current interim period. No withdrawal of the global expansion or business policy is indicated. - FY2025-H1RestatedAnnual report
「Fluralaner (active pharmaceutical ingredient for veterinary drugs) posted higher revenue.」
As in the second and third quarters of the previous fiscal year, the explanation states that fluralaner posted higher revenue. - FY2024AdvancedAnnual report
「Products from MSD Animal Health (or Merck Animal Health) containing fluralaner, a compound invented by the Company, are sold in more than 100 countries worldwide, including Japan, primarily as oral tablets for dogs and cats to control external parasites such as fleas and ticks (brand name: Bravecto®**). In recent years, the pet product lineup has been expanded to include Bravecto® PLUS, a feline combination product with an internal-parasite treatment, Bravecto® 1-Month Chews for puppies aged 8 weeks and older, and the canine injectable Bravecto® Quantum.」
The number of countries selling Bravecto-related products exceeded 100, and the pet product lineup was expanded to include the canine injectable Bravecto Quantum. - FY2024-Q3RestatedAnnual report
「Fluralaner (active pharmaceutical ingredient for veterinary drugs) posted higher revenue.」
As in the previous quarter, the explanation states that fluralaner posted higher revenue. - FY2024-Q2ReframedAnnual report
「Fluralaner (active pharmaceutical ingredient for veterinary drugs) posted higher revenue.」
The explanation states that fluralaner, which posted lower revenue in the first quarter of the previous fiscal year, posted higher revenue in the second quarter of the current fiscal year. - FY2024-Q1Decrease in revenueAnnual report
「Fluralaner (active pharmaceutical ingredient for veterinary drugs) posted lower revenue.」
Fluralaner posted lower revenue in the first quarter of the current fiscal year. No overseas product expansion or withdrawal of the business policy is indicated. - FY2023AdvancedAnnual report
「Livestock products include the drinking-water additive Exzolt®** or エグゾルト®** for controlling poultry red mites (a type of blood-sucking mite) in chickens. It has been approved in Asia, including Japan, as well as Europe, South America, Africa and the Middle East, and the number of registered countries has exceeded 70 (as of April 2023). Exzolt®** for controlling fleas and ticks in cattle was also approved in Brazil in March 2022 and Mexico in May 2022.」
Exzolt was registered in more than 70 countries, and the cattle product was approved in Brazil and Mexico, indicating progress in the regional and product expansion of veterinary drugs. - FY2023-Q3RestatedAnnual report
「Fluralaner (active pharmaceutical ingredient for veterinary drugs) posted higher revenue after customer inventory adjustments ended in the previous fiscal year.」
As in the previous quarter, the explanation attributes higher revenue from fluralaner to the end of customer inventory adjustments. - FY2023-Q2RestatedAnnual report
「Fluralaner (active pharmaceutical ingredient for veterinary drugs) posted higher revenue after customer inventory adjustments ended in the previous fiscal year.」
As in the previous quarter, the explanation attributes higher revenue from fluralaner to the end of customer inventory adjustments. - FY2023-Q1AdvancedAnnual report
「Fluralaner (active pharmaceutical ingredient for veterinary drugs) posted higher revenue after customer inventory adjustments ended in the previous fiscal year.」
The end of customer inventory adjustments and higher revenue indicate an improvement in business conditions from the previous revenue declines caused by customer inventory impacts. - FY2022AdvancedAnnual report
「Products from MSD Animal Health (or Merck Animal Health) containing fluralaner, a compound invented by the Company, are sold in more than 100 countries worldwide, including Japan, primarily as oral tablets for dogs and cats to control external parasites such as fleas and ticks (brand name: Bravecto®**). In recent years, the pet product lineup has been expanded to include products such as Bravecto® PLUS, a feline combination product with an internal-parasite treatment, and Bravecto® 1-Month Chews for puppies aged 8 weeks and older.」
The number of countries selling the products remained at 100, while the pet product lineup was expanded to include Bravecto® PLUS and 1-Month Chews. - FY2022-Q2ReframedAnnual report
「Fluralaner (active pharmaceutical ingredient for veterinary drugs) posted lower revenue as shipments declined due to the impact of customer inventories and other factors, despite strong royalty income.」
Royalty income was strong, but shipments and revenue declined due to the impact of customer inventories and other factors. The explanation has shifted from focusing mainly on higher revenue due to the change in recognition timing following the adoption of the accounting standard in the previous quarter to discussing shipment and revenue trends separately. - FY2022-Q1ReframedAnnual report
「Fluralaner (active pharmaceutical ingredient for veterinary drugs) posted higher revenue because, following the adoption from the current fiscal year of the Accounting Standard for Revenue Recognition and related standards, the timing of royalty recognition changed from twice a year to four times a year.」
Although fluralaner posted higher revenue, the explanation attributes this not to increased product shipments but to the change in the timing of royalty recognition from twice a year to four times a year resulting from the adoption of the revenue recognition accounting standard. - FY2021AdvancedAnnual report
「Products from MSD Animal Health (or Merck Animal Health) containing fluralaner, a compound invented by the Company, are sold in 100 countries worldwide, including Japan, primarily as oral tablets for dogs and cats to control external parasites such as fleas and ticks (brand name: Bravecto®**). The drinking-water additive Exzolt®*＊ for controlling poultry red mites (a type of blood-sucking mite) in chickens has also been approved in Europe, South America, Asia, Africa, the Middle East and Japan, where it is marketed as エグゾルト®**, and the number of registered countries has exceeded 70 (as of March 2021).」
The number of countries selling Bravecto-related products increased from 87 to 100 worldwide, while Exzolt was approved in more than 70 countries. - FY2021-Q3RestatedAnnual report
「Fluralaner (active pharmaceutical ingredient for veterinary drugs) posted lower revenue due to the impact of customer inventories and other factors.」
Revenue from fluralaner continues to decline due to the impact of customer inventories and other factors. No change in the business development policy is indicated. - FY2021-Q2RestatedAnnual report
「Fluralaner (active pharmaceutical ingredient for veterinary drugs) posted lower revenue due to the impact of customer inventories and other factors.」
Revenue from fluralaner continues to decline due to the impact of customer inventories and other factors. No change in the business development policy is indicated. - FY2021-Q1RestatedAnnual report
「Revenue from fluralaner (an active pharmaceutical ingredient for veterinary medicines) declined due to the impact of customer inventories.」
Revenue from fluralaner continues to decline due to the impact of customer inventories. No change or withdrawal of the business development policy is indicated. - FY2020-Q3RestatedAnnual report
「Revenue from fluralaner (an active pharmaceutical ingredient for veterinary medicines) declined due to the impact of customer inventories.」
Although lower revenue due to the impact of customer inventories has continued, there is no mention of a change in or withdrawal of the policy for the fluralaner business. - FY2020-Q2ReframedAnnual report
「Revenue from fluralaner (an active pharmaceutical ingredient for veterinary medicines) declined due to the impact of customer inventories, but exceeded the initial plan.」
The explanation has changed from lower revenue due to "inventory adjustments" in the previous quarter to lower revenue due to the impact of customer inventories. The company nevertheless states that it exceeded the initial plan. - FY2020-Q1Lower revenue due to inventory adjustmentsAnnual report
「Revenue from fluralaner (an active pharmaceutical ingredient for veterinary medicines) declined due to inventory adjustments, but exceeded the initial plan.」
The company explained that fluralaner revenue declined due to inventory adjustments, while exceeding the initial plan. - FY2019-Q3RestatedAnnual report
「Fluralaner shipments remained steady.」
The company explained that fluralaner shipments remained steady and continues to develop the product's business. - FY2019-Q1RestatedAnnual report
「Expansion of fluralaner (an active pharmaceutical ingredient for veterinary medicines) shipments」
The company reported an increase in fluralaner shipments, indicating that development of the product's business continues. - FY2018AdvancedAnnual report
「The countries selling the oral tablets for dogs and topical spot-on products for dogs and cats reached 87 worldwide, including Japan (as of March 2018). In addition, a new livestock product, Exzolt®, a drinking-water additive for controlling poultry red mites, a type of blood-feeding mite, was approved and launched in Europe in 2017.」
The number of countries selling Bravecto-related products increased from 80 to 87, and product development progressed, including the approval and launch of Exzolt for livestock in Europe. - FY2018-Q3RestatedAnnual report
「Shipments of fluralaner (an active pharmaceutical ingredient for veterinary medicines) remained steady, while sales of Roundup Maxload AL (a household herbicide) and Althea (a herbicide for paddy rice) were also firm. In addition, shipments of agrochemicals for overseas markets were strong.」
The company explained that shipments and sales of fluralaner, herbicides, and agrochemicals for overseas markets were firm or strong. - FY2018-Q2RestatedAnnual report
「Shipments of fluralaner (an active pharmaceutical ingredient for veterinary medicines) remained steady, while sales of Roundup Maxload AL (a household herbicide) and Althea (a herbicide for paddy rice) were also firm.」
The company explained that shipments of fluralaner remained steady and sales of related agricultural chemicals were also firm. - FY2017First statedAnnual report
「Bravecto™, an ectoparasiticide containing fluralaner, a compound invented by the Company, has seen expanded sales by MAH (Merck Animal Health, the animal health division of Merck & Co., Inc. in the United States, also known as MSD Animal Health). The number of countries selling its oral tablets for dogs reached 80 worldwide, including Japan (as of March 2017). In addition, topical spot-on products for dogs and cats received marketing approval in Europe (EU) and the United States from 2016, and were launched for cats in 2016 and dogs in 2017.」
The number of countries selling the oral product for dogs reached 80 worldwide, and the topical products for dogs and cats were approved and launched in Europe and the United States. The company is also strengthening its production system to meet strong demand.